Evaluación de la utilidad clínica del biomarcador SDMA (Dimetil Arginina Simétrica) en perros y gatos diagnosticados con patología renal de la Clínica Veterinaria “Entre Caninos” en el cantón de Samborondón, Ecuador.

Abstract

Currently, when a kidney problem is detected in dogs and cats, it is when kidney disease is in an advanced stage and there is already very little to do for the patient, two years ago symmetric dimethylarginine (SDMA) was incorporated into the country, which is an excellent indirect marker of glomerular filtration rate in dogs and cats, in turn it is an indicator of renal function that detects a low percentage such as 25% of loss of renal function, it is more reliable than urea and creatinine as an indicator of Renal function, as it is not affected by extrarenal factors, it is also an early indicator of progressive loss of renal function, which sometimes increases before other parameters. An increase in this marker can also help as an indicator of other concomitant diseases that may have a secondary signal in kidney functions. Today most veterinary laboratories offer this marker in their catalogue, for which helps Veterinarian to be able to promptly solve cases in pets. The purpose of this work is to analyze SDMA and other kidney disease markers such as urea and creatinine and to verify their clinical utility in the diagnosis of kidney problems in dogs and cats. The type of study sample will be casual or incidental sampling, in which 50 dogs and 50 cats will be part in this investigation that will be attended in the Veterinary Clinic "Entre Caninos" with clinical signs compatible with kidney problems that are carried out the biomarker test SDMA, using a 700 microliter blood sample packed with lithium heparin, and placed with the SDMA biomarker slide and reagent to be analyzed in the Catalyst One. In addition, this research will be non-experimental and will have a quantitative and comparative focus, descriptive and correlational in scope. The main objective is to analyze the evaluation of the clinical utility of the biomarker SDMA (Symmetric Dimethyl Arginine).